1.	Phase I/II Trial of Leuvectin as an Immunotherapeutic Agent by Direct Gene Transfer in Patients With Metastatic Melanoma, Renal Cell Carcinoma, and Sarcoma (Summary Last Modified 01/98) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MAYO-960106, VCL-1102-102, NCI-G97-1282
2.	Phase I/II Study of Leuvectin in Patients With Locally Recurrent Organ-Confined Prostate Cancer After Radiotherapy Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9906108, VCL-1102-203, NCI-G00-1721, NCT00005072
3.	Phase II Study of Neoadjuvant Leuvectin Followed by Retropubic Prostatectomy in Patients With Stage II or III Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9901077-03B, VCL-1102-202, NCI-G99-1568, NCT00004050
4.	A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IM01-101, NCT00223899